EP1151002A4 - Anticorps specifiques au kdr et leurs utilisations - Google Patents

Anticorps specifiques au kdr et leurs utilisations

Info

Publication number
EP1151002A4
EP1151002A4 EP00913280A EP00913280A EP1151002A4 EP 1151002 A4 EP1151002 A4 EP 1151002A4 EP 00913280 A EP00913280 A EP 00913280A EP 00913280 A EP00913280 A EP 00913280A EP 1151002 A4 EP1151002 A4 EP 1151002A4
Authority
EP
European Patent Office
Prior art keywords
kdr
antibodies specific
antibodies
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00913280A
Other languages
German (de)
English (en)
Other versions
EP1151002A1 (fr
Inventor
Zhenping Zhu
Larry Witte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImClone LLC
Original Assignee
ImClone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImClone Systems Inc filed Critical ImClone Systems Inc
Publication of EP1151002A1 publication Critical patent/EP1151002A1/fr
Publication of EP1151002A4 publication Critical patent/EP1151002A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP00913280A 1999-01-29 2000-01-28 Anticorps specifiques au kdr et leurs utilisations Withdrawn EP1151002A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24073699A 1999-01-29 1999-01-29
US11772699P 1999-01-29 1999-01-29
US240736 1999-01-29
US117726P 1999-01-29
PCT/US2000/002180 WO2000044777A1 (fr) 1999-01-29 2000-01-28 Anticorps specifiques au kdr et leurs utilisations

Publications (2)

Publication Number Publication Date
EP1151002A1 EP1151002A1 (fr) 2001-11-07
EP1151002A4 true EP1151002A4 (fr) 2002-05-02

Family

ID=26815579

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00913280A Withdrawn EP1151002A4 (fr) 1999-01-29 2000-01-28 Anticorps specifiques au kdr et leurs utilisations

Country Status (7)

Country Link
EP (1) EP1151002A4 (fr)
JP (1) JP2002536968A (fr)
CN (1) CN1345334A (fr)
AU (1) AU3475100A (fr)
CA (1) CA2361553A1 (fr)
IL (1) IL144578A0 (fr)
WO (1) WO2000044777A1 (fr)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2639020T3 (es) 1998-11-27 2017-10-25 Ucb Pharma S.A. Composiciones y métodos para incrementar la mineralización de la substancia ósea
JP4860877B2 (ja) 2000-03-07 2012-01-25 ジョンズ・ホプキンス・ユニバーシティ シアロアドへジンファクター−２抗体
US20030092091A1 (en) 2000-03-07 2003-05-15 Abrahamson Julie A. Sialoadhesin factor-2 antibodies
AU2001264946A1 (en) * 2000-05-24 2001-12-03 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
AU8901901A (en) * 2000-09-14 2002-03-26 Biogen Inc Tweak receptor agonists as anti-angiogenic agents background
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
EP1361892A4 (fr) * 2001-01-17 2004-10-13 Trubion Pharmaceuticals Inc Proteines de fusion d'immunoglobuline de domaine de liaison
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2003002144A1 (fr) * 2001-06-26 2003-01-09 Imclone Systems Incorporated Anticorps bispecifiques se liant aux recepteurs vegf
GB0124317D0 (en) * 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
WO2004065621A1 (fr) 2002-03-01 2004-08-05 Dyax Corp. Peptides de liaison kdr et vegf/kdr et leur utilisation a des fins diagnostiques et therapeutiques
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
SI2301587T1 (sl) * 2002-03-01 2014-11-28 Dyax Corp. KDR in VEGF/KDR vezavni peptidi in njihova uporaba pri diagnozi
PT1916001E (pt) 2002-03-04 2011-07-18 Imclone Llc Anticorpos humanos específicos para kdr e suas utilizações
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
GB0312481D0 (en) * 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
WO2004106375A1 (fr) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Banque de fab pour la preparation de fab anti-vegf et antirabique
US20070036795A1 (en) 2003-06-09 2007-02-15 Samuel Waksal Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular agonist
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
AU2006214179A1 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
AU2006272555B2 (en) 2005-07-25 2012-03-08 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
KR101464385B1 (ko) 2006-04-19 2014-11-21 노파르티스 아게 ６-ｏ-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 ｃｓｆ-１ｒ 신호전달의 억제 방법
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
CN101679266B (zh) 2007-03-01 2015-05-06 诺华股份有限公司 Pim激酶抑制剂及其应用方法
AU2008254425A1 (en) 2007-05-21 2008-11-27 Novartis Ag CSF-1R inhibitors, compositions, and methods of use
WO2009002495A1 (fr) 2007-06-27 2008-12-31 Merck & Co., Inc. Dérivés de 4-carboxybenzylamino utilisés en tant qu'inhibiteurs de l'histone désacétylase
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
CN101945853B (zh) 2007-12-21 2014-08-20 配体药物公司 选择性雄激素受体调节剂(sarm)及其应用
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
MX2010011168A (es) 2008-04-15 2010-12-21 Pharmacyclics Inc Inhibidores selectivos de histona-desacetilasa.
EP2413932A4 (fr) 2009-04-01 2012-09-19 Merck Sharp & Dohme Inhibiteurs de l'activité akt
CN101531718B (zh) * 2009-04-22 2011-11-02 中国人民解放军南京军区军事医学研究所 抗VEGFR-2抗体嵌合Fab抗体片段及其制备方法、应用
US8765747B2 (en) 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
US8128932B2 (en) 2009-08-17 2012-03-06 Shanghai Aosaiersi Biotech Co., Ltd. Anti-VEGFR monoclonal antibody, method of making and uses thereof
GB201005063D0 (en) * 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
CA2777043C (fr) 2009-10-14 2015-12-15 Schering Corporation Piperidines substituees qui accroissent l'activite de p53, et utilisations de ces composes
BR112012023021A2 (pt) 2010-03-16 2016-05-31 Dana Farber Cancer Inst Inc compostos de indazol e seus usos
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
EP2584903B1 (fr) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
WO2012004631A2 (fr) 2010-07-07 2012-01-12 Tubitak Structures d'anticorps recombinants qui se lient au facteur de croissance endothélial vasculaire 2 (vegfr-2/kdr) et bloquent son activité
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (fr) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (fr) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. INHIBITION FACILITÉE PAR L'INTERFÉRENCE D'ARN DE L'EXPRESSION D'UN GÈNE AU MOYEN D'ACIDES NUCLÉIQUES INTERFÉRENTS COURTS (siNA)
WO2012087772A1 (fr) 2010-12-21 2012-06-28 Schering Corporation Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
JP2014509588A (ja) 2011-03-01 2014-04-21 アムジエン・インコーポレーテツド 二特異性結合剤
US9145457B2 (en) 2011-03-25 2015-09-29 Amgen Inc. Sclerostin antibody crystals and formulations thereof
WO2012143879A1 (fr) 2011-04-21 2012-10-26 Piramal Healthcare Limited Forme cristalline d'un sel d'un dérivé de morpholinosulfonylindole et son procédé de préparation
TWI577693B (zh) 2011-05-31 2017-04-11 江蘇康緣藥業股份有限公司 聚（ａｄｐ-核糖）聚合酶之三環抑制劑
ES2667554T3 (es) 2011-08-04 2018-05-11 Amgen Inc. Método para el tratamiento de los defectos de espacio óseo
EP2770987B1 (fr) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
KR20190120401A (ko) 2011-12-28 2019-10-23 암젠 인크 항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법
WO2013157953A1 (fr) 2012-04-20 2013-10-24 Merus B.V. Procédés et moyens de production de molécules de type ig
EP3919620A1 (fr) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
JP6770312B2 (ja) 2012-07-05 2020-10-14 ユセベ ファルマ ソシエテ アノニム 骨疾患の治療
CA2882950A1 (fr) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Nouveaux composes inhibiteurs de erk
EP2909194A1 (fr) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibiteurs de cycline-dépendante kinase 7 (cdk7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
SMT201700595T1 (it) 2012-11-28 2018-03-08 Merck Sharp & Dohme Composizioni e metodi per trattare il cancro
WO2014100065A1 (fr) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Imidazopyridines substituées en tant qu'inhibiteurs de hdm2
WO2014120748A1 (fr) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
US9682154B2 (en) 2013-02-04 2017-06-20 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
WO2015034925A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides circulaires
WO2015058126A1 (fr) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Composés hétéroaromatiques utiles dans le traitement de maladies prolifératives
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (fr) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Inhibiteurs de janus kinase et leurs utilisations
JP2017515859A (ja) 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3262216A4 (fr) * 2015-02-24 2018-12-05 Academia Sinica Banque de fragments variables monocaténaires présentés sur phage
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
WO2016176503A1 (fr) 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Traitement du mélanome pd-l1 négatif à l'aide d'un anticorps anti-pd-1 et d'un anticorps anti-ctla-4
EP3288980B1 (fr) 2015-04-28 2021-03-10 Bristol-Myers Squibb Company Traitement du mélanome pd-l1 positif à l'aide d'un anticorps anti-pd-1
WO2016196389A1 (fr) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Traitement du néphrocarcinome
CA2986441A1 (fr) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Therapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases
DK3858859T3 (da) 2015-07-14 2025-12-15 Bristol Myers Squibb Co Fremgangsmåde til behandling af kræft under anvendelse af en immun checkpointinhibitor; antistof som binder til programmeret død-1 receptor (pd-1) eller programmeret død ligand 1 (pd-l1)
WO2017044858A2 (fr) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dépendantes
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
EP3475275B1 (fr) 2016-06-23 2024-04-10 Merck Sharp & Dohme LLC 5-trifluorométhyl-oxadiazoles substitués en 3-aryle et hétéroaryle en tant qu'inhibiteurs de l'histone désacétylase 6 (hdac6)
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
JP7160833B2 (ja) 2017-04-13 2022-10-25 サイロパ ビー．ブイ． 抗ｓｉｒｐアルファ抗体
WO2019094312A1 (fr) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
EP3706742B1 (fr) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
WO2019148412A1 (fr) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anticorps bispécifiques anti-pd-1/lag3
EP3774879B1 (fr) 2018-03-30 2026-01-28 Amgen Inc. Variants d'anticorps anti-c-terminal
EP3810132A4 (fr) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase de la famille taire et utilisations correspondantes
WO2020033285A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2020033282A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
EP3833667B1 (fr) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
CA3108388A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
CN113164477A (zh) 2018-12-14 2021-07-23 达纳-法伯癌症研究所股份有限公司 C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途
AU2020257397B2 (en) 2019-04-19 2026-02-26 Ligand Pharmaceuticals Inc. Crystalline forms and methods of producing crystalline forms of a compound
ES3074517T3 (en) 2019-12-17 2026-07-21 Merck Sharp & Dohme Llc 4-(3,4-dihydroisoquinolin-2(1h)-yl)-3-hydroxypiperidine derivatives as prmt5 inhibitors for the treatment of cancer and sickle cell disease
EP4076459B1 (fr) 2019-12-17 2026-04-29 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
ES3022307T3 (en) 2019-12-17 2025-05-28 Merck Sharp & Dohme Llc Prmt5 inhibitors
EP4076460B1 (fr) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC Dérivés de 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine] en tant qu'inhibiteurs de prmt5 pour le traitement du cancer
CA3215430A1 (fr) * 2021-04-14 2022-10-20 Suzhou Transcenta Therapeutics Co., Ltd. Nouveaux anticorps anti-hvegfr2
WO2024180169A1 (fr) 2023-03-02 2024-09-06 Carcimun Biotech Gmbh Moyens et procédés de diagnostic du cancer et/ou d'une maladie inflammatoire aiguë
DE212025000115U1 (de) 2024-07-30 2026-06-18 Sairopa B.V. Anti-SIRP Alpha-Antikörperformulierungen und ihre Verwendung

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016353A1 (fr) * 1990-04-23 1991-10-31 Corvas International N.V. Derives d'anticorps specifiques au thrombus
WO1998011223A1 (fr) * 1996-09-11 1998-03-19 Schering Aktiengesellschaft Anticorps monoclonaux diriges contre le domaine extracellulaire de la proteine du recepteur kdr de vegf humain
WO1999040118A1 (fr) * 1998-02-04 1999-08-12 Kyowa Hakko Kogyo Co., Ltd. Anticorps diriges contre le recepteur kdr humain du vegf
WO1999060025A1 (fr) * 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Anticorps recombines de gene
EP1086705A1 (fr) * 1998-05-20 2001-03-28 Kyowa Hakko Kogyo Co., Ltd. Inhibiteurs de l'activite du facteur de croissance endothelial vasculaire (vegf)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016353A1 (fr) * 1990-04-23 1991-10-31 Corvas International N.V. Derives d'anticorps specifiques au thrombus
WO1998011223A1 (fr) * 1996-09-11 1998-03-19 Schering Aktiengesellschaft Anticorps monoclonaux diriges contre le domaine extracellulaire de la proteine du recepteur kdr de vegf humain
WO1999040118A1 (fr) * 1998-02-04 1999-08-12 Kyowa Hakko Kogyo Co., Ltd. Anticorps diriges contre le recepteur kdr humain du vegf
WO1999060025A1 (fr) * 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Anticorps recombines de gene
EP1086705A1 (fr) * 1998-05-20 2001-03-28 Kyowa Hakko Kogyo Co., Ltd. Inhibiteurs de l'activite du facteur de croissance endothelial vasculaire (vegf)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HICKLIN D J ET AL: "MONOCLONAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR (KDR) ANTIBODIES WHICH ARE INHIBITORS OF VEGF BINDING AND ANTAGONISTS OF VEGF-STIMULATED SIGNALING AND GROWTH OF HUMAN ENDOTHELIAL CELLS", PROCEEDINGS OF THE 89TH. ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. NEW ORLEANS, LA, MARCH 28 - APRIL 1, 1998, PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, PHILADELPHIA, PA: AACR, US, vol. 39, March 1998 (1998-03-01), pages 96, XP000918907 *
See also references of WO0044777A1 *
WITTE L ET AL: "MONOCLONAL ANTIBODIES TARGETING THE VEGF RECEPTOR-2 (FLK1/KDR) AS AN ANTI-ANGIOGENIC THERAPEUTIC STRATEGY", CANCER AND METASTASIS REVIEWS, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, NL, vol. 17, no. 2, 1998, pages 155 - 161, XP000940443, ISSN: 0167-7659 *
ZHU Z ET AL: "Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 58, no. 15, 1 August 1998 (1998-08-01), pages 3209 - 3214, XP002141908, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
CN1345334A (zh) 2002-04-17
AU3475100A (en) 2000-08-18
CA2361553A1 (fr) 2000-08-03
WO2000044777A1 (fr) 2000-08-03
IL144578A0 (en) 2002-05-23
EP1151002A1 (fr) 2001-11-07
JP2002536968A (ja) 2002-11-05

Similar Documents

Publication Publication Date Title
IL144578A0 (en) Antibodies specific to kdr and uses thereof
MXPA03001590A (es) Anticuerpos para la il-1beta humana.
IL190220A0 (en) Novel composition and use
TWI316088B (en) Anti-tnf alpha antibodies and their uses
EP1299168A4 (fr) Biocollecteur et concentrateur a mini-cyclones
GB9911569D0 (en) Antibodies
GB9927332D0 (en) Novel antibody and uses thereof
AU2608602A (en) Silensed anti-cd28 antibodies and use thereof
IL148247A (en) Vaccine and its uses
IL149614A0 (en) Novel use of antibodies as vaccines
EG22491A (en) Rest-breaking composition and use thereof
AU7522401A (en) Non-agonistic antibodies to human gp39, compositions containing, and therapeuticuse thereof
GB9907687D0 (en) Assays methods and means
AU2002365894A8 (en) Antibodies to magmas and uses thereof
GB2351459B (en) Improvements in and relating to the application of materials
AP2002002429A0 (en) Novel composition and emulsifier
GB0012193D0 (en) Materials and methods relating to encapsulation
GB9911606D0 (en) Composition and use
GB9929581D0 (en) Comjpositions and their use
IL145152A0 (en) Novel protein and its use
HU9902379D0 (en) Firering and dust-separator apparatous to utilize plant-wastes by air-protecting way
EG24062A (en) Novel composition and use
GB9906754D0 (en) Therapeutic antibody composition and use
GB9901682D0 (en) Therapeutic antibody composition and use
GB9907151D0 (en) Therapeutic antibody composition and use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010829

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20020315

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20021223

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030703